Diabetic cardiomyopathy, i.e. the ventricular dysfunction in the absence of hypertension or coronary arterial disease, is a common complication of diabetes mellitus that leads to a heightened risk of heart failure and death among diabetic patients. This contractile dysfunction could be associated to mitochondrial dysfunction, in which mitochondrial biogenesis could emerge as a compensatory mech...

Diabetes is a risk factor for heart failure and cardiovascular mortality with specific changes to myocardial metabolism, energetics, structure, and function. The gradual impairment of insulin production and signalling in diabetes is associated with elevated plasma fatty acids and increased myocardial free fatty acid uptake and activation of the transcription factor PPARα. The increased free fat...

Patients with diabetes have an increased incidence of heart failure, even after analyses have controlled for coronary artery disease and hypertension. Thus, as diabetic cardiomyopathy (DCM) has become a well recognized entity among clinicians, a better understanding of its development is necessary for the early diagnosis and the future treatment of diabetes-associated cardiovascular disease. In...

? ?????? ???????? ???????????????? ??????????? ??????? ?? ?????????????, ????????? ? ????????? ????????????? ??????????????. ???????? ?????? ???????? ????????? ??????????? ?????????????? ??????????? ????? ????????. ??? ??????????????????? ????????? ????????? ? ?????????? ?????????????? ?????????, ????????? ??????????????, ??????????????????????? ?????????????. ????????? ?????? ??????? ????? ???...

Diabetic cardiomyopathy is characterized by diastolic and systolic cardiac dysfunction, yet no therapeutic drug to specifically treat it. Hexarelin has been demonstrated to improve heart function in various types of cardiomyopathy via its receptor GHS-R. This experiment aims to test the effect of hexarelin on cardiomyocytes under experimental diabetes. Streptozotocin (STZ, 65 mg/kg)-induced dia...

Diabetic cardiomyopathy, a major cardiac complication, contributes to heart remodelling and heart failure. Our previous study discovered that CCAAT/enhancer-binding protein β (C/EBPβ), a transcription factor that belongs to a family of basic leucine zipper transcription factors, interacts with the angiotensin-converting enzyme 2 (ACE2) promoter sequence in other disease models. Here, we aimed t...